ReviewClinical epigenetics2026
Epigenetic collapse establishes transcriptional bottlenecks in malignant rhabdoid tumor.
Review in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Malignant rhabdoid tumor (MRT) is an aggressive pediatric cancer defined by biallelic loss of SMARCB1 and characterized by an unusually simple mutational landscape. Despite the absence of recurrent activating oncogenic mutations, MRT exhibits highly malignant behavior, creating a clinical paradox. Loss of SMARCB1 disrupts SWI/SNF-mediated chromatin organization, leading to enhancer redistribution and reorganization of transcriptional control. MRT therefore provides a defined model to examine how structural disruption of chromatin regulation sustains tumor maintenance in the absence of mutation-driven signaling activation. We propose that this epigenetic collapse reduces regulatory diversity and concentrates control of essential survival and cell-cycle programs within limited transcriptional nodes. We define this structural state as transcriptional bottleneck formation, in which tumor viability depends on concentrated transcriptional control rather than recurrent genetic alteration. Bottleneck nodes are characterized by enriched chromatin occupancy at survival and cell-cycle genes, limited compensatory regulation, and functional sensitivity to perturbation. In MRT, members of the RUNX family illustrate a representative concentrated transcriptional node linking chromatin reorganization to regulation of BIRC5 and related survival genes. This disease-focused perspective supports an architecture-centered therapeutic strategy aimed at disrupting concentrated transcriptional control. Identification of biomarkers reflecting this architectural state may facilitate selection of bottleneck-directed interventions in MRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.